A tighter archive for life-science signals.
Search once, then narrow by source or topic.
FDA reverses course on Moderna’s flu vaccine
FDA reverses course on Moderna’s flu vaccine
Compass, with Phase 3 hits, ready to take psilocybin to the FDA
Compass, with Phase 3 hits, ready to take psilocybin to the FDA
Ocular claims a win with eye drug data even as shares sink
Ocular claims a win with eye drug data even as shares sink
How to evaluate prospective diagnostic laboratory partners for your patient support program
How to evaluate prospective diagnostic laboratory partners for your patient support program
Selecting the optimal cell therapy manufacturing platform
Selecting the optimal cell therapy manufacturing platform
Vertex’s CRISPR therapy rebounds in latest earnings
Vertex’s CRISPR therapy rebounds in latest earnings
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs
FDA removes box warning for 6 menopausal therapies
FDA removes box warning for 6 menopausal therapies
Ultragenyx cuts jobs as it seeks path to profit in 2027
Ultragenyx cuts jobs as it seeks path to profit in 2027
Moderna shares jump as company affirms growth outlook
Moderna shares jump as company affirms growth outlook
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor
Seres to lay off staff, pause top program in latest reboot
Seres to lay off staff, pause top program in latest reboot
Lowering drug costs is on Republicans’ minds. Democrats say GOP policies don’t help.
Lowering drug costs is on Republicans’ minds. Democrats say GOP policies don’t help.
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis
CDC moves to cut $600M in grants to Democrat-led states
CDC moves to cut $600M in grants to Democrat-led states
Madrigal turns to RNAi drugs from China to bolster MASH pipeline
Madrigal turns to RNAi drugs from China to bolster MASH pipeline
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page